Orchestra BioMed Holdings, Inc. (OBIO) Stock

Orchestra BioMed Holdings, Inc. (OBIO) is a Healthcare stock trading at $5.42 (as of 2026-08-20), with a market capitalization of $325.77M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing and commercializing medical therapies and devices. Its candidates include BackBeat Cardiac Neuromodulation Therapy for hypertension and Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease, alongside minimally invasive FreeHold retractors, with development and commercialization partnerships involving Medtronic and Terumo.

Understand Orchestra BioMed Holdings, Inc.: how it makes money

Orchestra BioMed Holdings develops biomedical therapies and minimally invasive surgical devices, including BackBeat Cardiac Neuromodulation Therapy for hypertension and Virtue Sirolimus AngioInfusion Balloon for atherosclerotic artery disease, and it pursues commercialization through collaborations such as its Medtronic partnership for BackBeat in pacemaker-indicated patients.

The company’s profit model is driven by successfully advancing and commercializing its flagship product candidates (and related device solutions), with strategic partners like Medtronic helping enable development and commercialization in specific patient contexts.

Business quality (Weak): Clear product-candidate focus and a named commercialization collaboration, but the provided data does not include segment revenue or operating metrics, and the reported operating margin for the latest period is deeply negative (-20069.1%), signaling significant operating losses.

Bull case

  • Flagship clinical pipeline for cardiovascular conditions: BackBeat CNT is aimed at treating hypertension, and Virtue SAB is aimed at treating atherosclerotic artery disease.
  • Named commercialization collaboration: Medtronic collaboration supports the development and commercialization of BackBeat CNT for hypertension in pacemaker-indicated patients.
  • Broader device offering within minimally invasive procedures: FreeHold retractors are positioned as minimally invasive surgical device solutions.

Bear case

  • Material operating losses in the latest reported period: The latest quarter shows an operating margin of -20069.1%, indicating substantial operating losses.
  • Limited provided operating detail: No official reportable segments or operational KPIs were provided in the available facts, which makes it harder to track product-level traction or progress using standard investor operating metrics.
Valuation — source: SEC EDGAR (first-party)
Price$5.42
Market Cap$325.77M
Price / Book16.86
Price / Sales278.67
FCF Yield-41.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$33.48M
Net Margin-157.4%
Revenue Growth (YoY)1169.2%
EPS Growth (YoY)-33.1%
FCF Growth (YoY)-2.7%
Financial Health — source: SEC EDGAR
Altman Z-Score-1.56 (distress)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderRTW INVESTMENTS, LP ($35.30M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEODavid Hochman
Employees70
CountryUS
IPO Date2020-08-04

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • AVITA Medical, Inc. (RCEL)
  • Embecta Corp. (EMBC)
  • Treace Medical Concepts, Inc. (TMCI)
  • Anika Therapeutics, Inc. (ANIK)
  • OraSure Technologies, Inc. (OSUR)
  • InfuSystem Holdings, Inc. (INFU)
  • Utah Medical Products, Inc. (UTMD)
  • Neuronetics, Inc. (STIM)
OBIO earnings history · OBIO institutional & insider holders · OBIO KPIs & operating metrics · OBIO financials · OBIO investor presentations & press releases · OBIO SEC filings · OBIO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.